文献速递食管与纵隔外科

肥胖对可切除食管癌治疗方式的影响

Impact of Obesity on Treatment Approach for Resectable Esophageal Cancer.
PubMed 文献 · Ann Thorac Surg · 2020-12-17

基于美国胸外科医师学会普胸外科数据库,回顾性分析2012至2016年8547例食管切除胃代食管患者,按体重指数分五组。肥胖和病态肥胖患者更常接受开放手术且手术时间更长,病态肥胖者中转开放率更高。分期检查和R0切除率无差异,但肥胖患者新辅助治疗及术前放疗使用较少,cT2N0期超重和肥胖患者新辅助治疗率更低。

要点

  • 肥胖和病态肥胖患者食管切除术更倾向开放入路,病态肥胖者中转开放风险更高。
  • 肥胖与R0切除率及淋巴结清扫无显著差异,分期检查相似。
  • 超重和肥胖cT2N0患者新辅助治疗使用率更低,cT3或淋巴结阳性者无差异。

核心结论

  • 较高的体重指数与食管切除术更常采用开放入路及术中中转开放相关。
  • 分期检查和手术肿瘤学结局相似,但超重和肥胖cT2N0患者较少接受新辅助治疗。

研究设计与样本

  • 回顾性队列研究,使用美国胸外科医师学会普胸外科数据库。
  • 纳入2012至2016年接受食管切除胃代食管重建的全部患者,共8547例,按体重指数分五组。
  • 采用多因素逻辑回归模型评估体重指数与手术技术、切除、淋巴结清扫、分期和新辅助治疗的关系。

主要发现

  • 肥胖和病态肥胖患者较正常体重患者更可能接受开放手术(OR 1.18,P = .016;OR 1.45,P = .007),手术时间更长。
  • 病态肥胖患者术中从微创中转开放的比例更高(OR 3.75,P = .001)。
  • R0切除率或淋巴结清扫无差异,分期检查相似。
  • 肥胖患者较少接受新辅助治疗(OR 0.75,P = .048),超重和肥胖患者较少接受术前放疗(OR 0.75,P = .017;OR 0.71,P = .010)。
  • 按分期分析,cT2N0期超重和肥胖患者较少接受新辅助治疗(OR 0.54,P = .016;OR 0.37,P < .001),cT3或淋巴结阳性疾病中新辅助治疗无差异。

临床怎么用

  • 对肥胖食管癌患者术前应评估微创手术难度及中转开放风险。
  • cT2N0期超重或肥胖患者需关注新辅助治疗决策是否充分。

局限性

  • 回顾性数据库研究,可能存在未测量混杂因素。
  • 原文未报告具体混杂因素调整列表及数据缺失情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With the prevalence of obesity and its known association with esophageal cancer, there is increasing need to understand how obesity affects treatment. METHODS: Using The Society of Thoracic Surgeons General Thoracic Surgery Database, we retrospectively evaluated all patients who underwent esophagectomy with gastric conduit reconstruction between 2012 and 2016. Patients were categorized into five body mass index groups. Associations between body mass index and surgical technique, resection, lymphadenectomy, staging, and neoadjuvant treatment were evaluated using multivariable logistic regression models. RESULTS: In all, 8547 patients were included in the analysis. Obese and morbidly obese patients were more likely to undergo open procedures compared with normal-weight patients (odds ratio [OR] 1.18, P = .016; and OR 1.45, P = .007), with longer operative times. Morbidly obese patients had a higher rate of intraoperative conversion from minimally invasive to open approaches (OR 3.75, P = .001). There were no differences in R0 resection or lymphadenectomy, and staging workup was similar. Obese patients were less likely to receive neoadjuvant therapy (OR 0.75, P = .048), and overweight and obese patients were less likely to receive preoperative radiation (OR 0.75, P = .017; and OR 0.71, P = .010). Analyzing by stage, overweight and obese patients with cT2N0 disease were less likely to receive neoadjuvant treatment (OR 0.54, P = .016; and OR 0.37, P < .001). There were no differences in neoadjuvant therapy for cT3 or node-positive disease. CONCLUSIONS: Higher body mass index is associated with increased use of open versus minimally invasive esophagectomy and intraoperative conversion. Whereas staging workup and oncologic outcomes of surgery are similar, overweight and obese patients with cT2N0 disease are less likely to undergo neoadjuvant treatments.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Sachdeva UM, Axtell AL, Kroese TE, et al. Impact of Obesity on Treatment Approach for Resectable Esophageal Cancer. Ann Thorac Surg. 2020. PMID: 33345782. doi:10.1016/j.athoracsur.2020.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。